The race to develop convenient weight-loss medications is heating up, and AstraZeneca has emerged as the latest contender with promising clinical trial results for its experimental daily pill, elecoglipron.
Data from a Phase 2 clinical trial published in The Lancet suggest that the oral GLP-1 drug helped overweight and obese adults lose up to 11.8% of their body weight over 36 weeks. While the results are encouraging, experts caution that larger Phase 3 studies are still needed to confirm its long-term safety and effectiveness.
If successful, elecoglipron could offer patients an alternative to injectable weight-loss drugs that currently dominate the market.
TL;DR
- AstraZeneca’s experimental oral weight-loss drug, elecoglipron, showed promising Phase 2 results.
- Participants lost up to 11.8% of their body weight after 36 weeks.
- The study involved 310 overweight or obese adults without diabetes.
- Nausea was the most commonly reported side effect.
- Larger Phase 3 trials are needed before the drug can receive regulatory approval.
- AstraZeneca is competing with Novo Nordisk and Eli Lilly in the fast-growing obesity drug market.
What is elecoglipron?
Elecoglipron is an investigational oral GLP-1 receptor agonist developed by AstraZeneca to treat obesity and support weight management.
Like injectable GLP-1 medications, the pill is designed to mimic a naturally occurring hormone that helps regulate:
- Appetite
- Hunger signals
- Food intake
- Blood sugar levels
- Gastric emptying
By increasing feelings of fullness and reducing appetite, GLP-1 medicines help many patients consume fewer calories, leading to weight loss.
Unlike popular injectable therapies, elecoglipron is taken as a once-daily pill, potentially offering a more convenient treatment option for many patients.
What did the Phase 2 trial find?
The randomized Phase 2 study enrolled 310 overweight or obese adults without diabetes.
Researchers evaluated multiple dose levels over several months.
The results showed:
- Up to 10.5% average weight loss after 26 weeks in the highest-dose group.
- Up to 11.8% average weight loss after 36 weeks.
- Weight loss increased over time, suggesting continued effectiveness throughout the study period.
Although the findings are encouraging, Phase 2 trials are primarily designed to assess safety, dosing, and preliminary effectiveness rather than provide definitive comparisons with existing treatments.
What side effects were reported?
The safety profile appeared broadly consistent with other GLP-1 medications currently on the market.
The most commonly reported side effect was:
- Nausea
Other gastrointestinal side effects commonly associated with GLP-1 drugs, such as vomiting, diarrhea, or constipation, may occur with this class of medications, although the study highlighted nausea as the primary adverse event.
Researchers said the overall tolerability was comparable to similar oral GLP-1 therapies.
How does elecoglipron compare with existing weight-loss drugs?
While direct comparisons cannot be made from this Phase 2 study, the reported weight-loss results are broadly in line with those seen in trials of other oral GLP-1 medications.
The obesity treatment market is currently led by:
- Novo Nordisk, maker of Wegovy and Ozempic.
- Eli Lilly, maker of Mounjaro and Zepbound.
Both companies are also expanding into oral GLP-1 therapies.
According to recent developments:
- Eli Lilly’s oral version of Mounjaro received U.S. approval under the brand name Foundayo.
- Novo Nordisk has already launched an oral version of Wegovy in the United States and recently secured regulatory approval in the European Union.
AstraZeneca’s positive trial results position the company as another major competitor in one of the pharmaceutical industry’s fastest-growing markets.
What do experts say?
Marie Spreckley, a weight management researcher at the University of Cambridge who was not involved in the study, said the findings are promising but should be interpreted cautiously.
She noted that the trial was not designed to directly compare elecoglipron with competing obesity medications.
According to Spreckley, larger and longer Phase 3 studies will be necessary to determine:
- Long-term weight-loss durability.
- Safety over extended use.
- Tolerability.
- How the drug compares with existing obesity and diabetes treatments.
Why are oral weight-loss drugs attracting so much attention?
Injectable GLP-1 medications have transformed obesity treatment over the past few years, but many patients remain reluctant to use weekly injections.
A daily pill could offer several potential advantages:
- Easier administration.
- Greater patient acceptance.
- Improved convenience.
- Potentially broader access.
- Increased treatment adherence.
Pharmaceutical companies see oral therapies as a major opportunity to expand access to obesity treatment worldwide.
What happens next?
Elecoglipron remains an experimental medicine and has not yet received regulatory approval for weight loss.
The next major milestone will be Phase 3 clinical trials involving larger numbers of participants over longer periods.
If those studies confirm the drug’s safety and effectiveness, AstraZeneca could eventually seek approval from regulators, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
Until then, experts emphasize that patients should not expect the drug to become available immediately, as the approval process typically requires additional years of clinical testing and regulatory review.